Biologics and Biosimilars: Transforming the Pharmacological Landscape

Abstract

Biologics and biosimilars are rapidly transforming the pharmacological landscape by offering novel approaches to treating a variety of diseases, including cancers, autoimmune disorders, and chronic conditions. Biologics, large and complex molecules derived from living organisms, have revolutionized the treatment of conditions that were once difficult or impossible to manage. As these drugs become more widely used, biosimilars—highly similar, but not identical, copies of biologics—have emerged to provide cost-effective alternatives. This paper explores the differences between biologics and biosimilars, their roles in modern healthcare, and the regulatory frameworks guiding their development and use. The growing use of biologics and biosimilars represents a paradigm shift in the treatment of complex diseases, offering new hope for patients while also presenting challenges for healthcare systems.